De‑Risking Biologics Development:
Practical Strategies to Move Faster from
Cell Line to Clinic
Presenters:
Sunit Maity, PhD Sunit Maity is a seasoned biopharmaceutical scientist with extensive experience in biologics and biosimilar development across academia and industry. He received his doctoral degree in developmental and cardiovascular biology from Leuven, Belgium, and began his industry career at Mermaid Pharmaceuticals in Hamburg, Germany, where he worked on target identification using model systems. He also conducted research at the Max Planck Institute, Germany, contributing to projects in CNS development.
After returning to India in 2007, Sunit joined Avesthagen, where he was head of the biopharmaceutical group and led the development of biosimilars, including recombinant proteins and monoclonal antibodies using mammalian expression systems. He subsequently joined Zumutor Biologics at its inception, serving as director of product development, leading process development and scale-up activities for novel monoclonal antibody programs in the immuno-oncology space.
Currently, he heads biopharmaceutical development at Syngene, where he continues to drive the development and advancement of complex biologics.
Samantha Hullah, PhD In her current role at Syngene, Samantha provides strategic technical and CMC guidance to prospective biologics clients and acts as a critical technical bridge between commercial and operations teams, ensuring seamless program alignment and delivery. Based in Cambridge, Massachusetts, and originally from the Northeast of England, she supports a global commercial organization with a focus on scientific rigor, operational excellence, and partnership success.
